- Home
- TVRD vs CYRX Comparison
TVRD vs CYRX Comparison
Compare TVRD & CYRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TVRD
- CYRX
- Stock Information
- Founded
- TVRD 2017
- CYRX 1999
- Country
- TVRD United States
- CYRX United States
- Employees
- TVRD N/A
- CYRX N/A
- Industry
- TVRD Biotechnology: Pharmaceutical Preparations
- CYRX Biotechnology: Pharmaceutical Preparations
- Sector
- TVRD Health Care
- CYRX Health Care
- Exchange
- TVRD Nasdaq
- CYRX Nasdaq
- Market Cap
- TVRD 246.5M
- CYRX 328.9M
- IPO Year
- TVRD N/A
- CYRX N/A
- Fundamental
- Price
- TVRD $22.15
- CYRX $7.31
- Analyst Decision
- TVRD Strong Buy
- CYRX Strong Buy
- Analyst Count
- TVRD 3
- CYRX 8
- Target Price
- TVRD $60.67
- CYRX $10.75
- AVG Volume (30 Days)
- TVRD 98.9K
- CYRX 585.5K
- Earning Date
- TVRD 08-21-2025
- CYRX 08-05-2025
- Dividend Yield
- TVRD N/A
- CYRX N/A
- EPS Growth
- TVRD N/A
- CYRX N/A
- EPS
- TVRD N/A
- CYRX N/A
- Revenue
- TVRD N/A
- CYRX $232,134,000.00
- Revenue This Year
- TVRD N/A
- CYRX N/A
- Revenue Next Year
- TVRD N/A
- CYRX $9.63
- P/E Ratio
- TVRD N/A
- CYRX N/A
- Revenue Growth
- TVRD N/A
- CYRX 11.75
- 52 Week Low
- TVRD $8.13
- CYRX $4.58
- 52 Week High
- TVRD $34.31
- CYRX $9.78
- Technical
- Relative Strength Index (RSI)
- TVRD N/A
- CYRX 59.38
- Support Level
- TVRD N/A
- CYRX $6.16
- Resistance Level
- TVRD N/A
- CYRX $7.96
- Average True Range (ATR)
- TVRD 0.00
- CYRX 0.44
- MACD
- TVRD 0.00
- CYRX 0.05
- Stochastic Oscillator
- TVRD 0.00
- CYRX 63.89
About TVRD Tvardi Therapeutics Inc. Common Stock
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.
About CYRX CryoPort Inc.
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. It operates in two reportable segments: Life Sciences Services and Life Sciences Products. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.